Hoya (OTCMKTS:HOCPY - Get Free Report) will likely be releasing its results before the market opens on Thursday, October 30th. Analysts expect Hoya to post earnings of $0.99 per share and revenue of $225.6147 billion for the quarter.
Hoya (OTCMKTS:HOCPY - Get Free Report) last announced its earnings results on Friday, August 1st. The technology company reported $1.05 earnings per share for the quarter, beating analysts' consensus estimates of $1.04 by $0.01. Hoya had a return on equity of 21.01% and a net margin of 23.57%.The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.47 billion. On average, analysts expect Hoya to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Hoya Stock Performance
Shares of OTCMKTS:HOCPY opened at $150.00 on Thursday. Hoya has a twelve month low of $97.49 and a twelve month high of $155.17. The firm has a market cap of $51.47 billion, a PE ratio of 37.50, a price-to-earnings-growth ratio of 3.14 and a beta of 1.03. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.46 and a current ratio of 5.19. The business has a fifty day moving average of $139.60 and a 200-day moving average of $126.34.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on HOCPY. Nomura Securities upgraded Hoya to a "strong-buy" rating in a research note on Monday, August 18th. The Goldman Sachs Group upgraded Hoya from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, July 23rd. Three analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat, Hoya presently has a consensus rating of "Strong Buy".
Read Our Latest Research Report on Hoya
About Hoya
(
Get Free Report)
HOYA Corporation, a med-tech company, provides high-tech and medical products worldwide. It operates through three segments: Life Care, Telecommunication, and Other. The company offers life care products, including eyeglass and contact lenses; medical endoscopes; intraocular lenses; laparoscopic surgical instruments; automatic endoscope cleaning equipment; and other medical related products, such as prosthetic ceramic fillers and metallic implants for orthopedics.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hoya, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hoya wasn't on the list.
While Hoya currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
